|Systematic (IUPAC) name|
|Legal status||Legal (UK) Legal (US)|
|Mol. mass||333.16 g/mol|
Flubromazepam is an invented name for a benzodiazepine derivative which was first made in 1962, but was never marketed and did not receive any further attention or study until it started to be sold as a designer drug in late 2012. It presumably has sedative and anxiolytic effects comparable to those of other benzodiazepine derivatives. A closely related compound 7-fluoro-5-(2-bromophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one, and another; 5-(2-Fluorophenyl)-7-bromo-1,3-dihydro-2H-1,4-benzodiazepin-2-one, also appears to have been sold under the same name. Active metabolites are still unknown to public but even though its legal status the metabolized show on drug tests. Its onset is around 4 hours and reaches its peak at 8 hours.
- Sternbach, L. H.; Fryer, R. I.; Metlesics, W.; Reeder, E.; Sach, G.; Saucy, G.; Stempel, A. (1962). "Quinazolines and 1,4-Benzodiazepines. VI.1a Halo-, Methyl-, and Methoxy-substituted 1,3-Dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones1b,c". The Journal of Organic Chemistry 27 (11): 3788. doi:10.1021/jo01058a010.
- Moosmann B, et al. Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples. Institute of Forensic Medicine, Forensic Toxicology, University Medical Center Freiburg, Freiburg, Germany